Search

Your search keyword '"Yates, Melinda S."' showing total 184 results
Start Over Author "Yates, Melinda S."
184 results on '"Yates, Melinda S."'

2. Insights into the complexity of the impostor phenomenon among trainees and professionals in STEM and medicine

Author

Lee, HwaYoung, Anderson, Cheryl B., Yates, Melinda S., Chang, Shine, and Chakraverty, Devasmita

Subjects
Education, Higher -- Psychological aspects, Psychological research, Impostor phenomenon -- Research, Psychology and mental health
Abstract

Although the imposter phenomenon (IP), characterized by fear of exposure as a fraud, is prevalent in higher education, studies disagree about its dimensionality, its relation to individual characteristics, and how IP relates to self-evaluation. Analyzing data from 959 graduate students and professionals in science, technology, engineering, mathematics (STEM), and medicine, we examined the psychometric properties of the Clance IP scale and evaluated IP's conceptual clarity in relation to demographics and self-evaluation. Factor analyses yielded three factors: Self-Doubt, Fear of Evaluation, and Luck. Older age groups, people currently not in-training, and men had lower sub-scale IP scores. We created four IP groups using factor scores and found that 'Fear IP' (low self-doubt/high fear) and 'High IP' (high self-doubt/high fear) groups reported less positive self-evaluations than 'Self-Doubt' IP (high self-doubt/low fear) and 'Low IP' (low self-doubt/low fear) groups. Findings suggest different types of IP that includes more strategic self-presentations of ability, and the defining feature of IP may be fear rather than self-doubt, with implications on training in higher education., Author(s): HwaYoung Lee [sup.1] , Cheryl B. Anderson [sup.1] , Melinda S. Yates [sup.2] , Shine Chang [sup.1] , Devasmita Chakraverty [sup.3] Author Affiliations: (1) grid.240145.6, 0000 0001 2291 4776, [...]

Published
2022
Full Text
View/download PDF

3. Mitochondrial defects and metabolic vulnerabilities in Lynch syndrome-associated MSH2-deficient endometrial cancer

Author

Bowen, Mikayla Borthwick, primary, Melendez, Brenda D, additional, Zhang, Qian, additional, Moreno, Diana, additional, Peralta, Leah, additional, Chan, Wai Kin, additional, Jeter, Collene, additional, Tan, Lin, additional, Zal, M. Anna, additional, Lorenzi, Philip L, additional, Dunner, Kenneth, additional, Yang, Richard K, additional, Broaddus, Russell R, additional, Celestino, Joseph, additional, Gokul, Nisha T, additional, Lu, Karen H, additional, Kim, Hyun-Eui, additional, Schmandt, Rosemarie, additional, and Yates, Melinda S, additional

Published
2024
Full Text
View/download PDF

4. Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy

Author

Vellano, Christopher P., White, Michael G., Andrews, Miles C., Chelvanambi, Manoj, Witt, Russell G., Daniele, Joseph R., Titus, Mark, McQuade, Jennifer L., Conforti, Fabio, Burton, Elizabeth M., Lastrapes, Matthew J., Ologun, Gabriel, Cogdill, Alexandria P., Morad, Golnaz, Prieto, Peter, Lazar, Alexander J., Chu, Yanshuo, Han, Guangchun, Khan, M. A. Wadud, Helmink, Beth, Davies, Michael A., Amaria, Rodabe N., Kovacs, Jeffrey J., Woodman, Scott E., Patel, Sapna, Hwu, Patrick, Peoples, Michael, Lee, Jeffrey E., Cooper, Zachary A., Zhu, Haifeng, Gao, Guang, Banerjee, Hiya, Lau, Mike, Gershenwald, Jeffrey E., Lucci, Anthony, Keung, Emily Z., Ross, Merrick I., Pala, Laura, Pagan, Eleonora, Segura, Rossana Lazcano, Liu, Qian, Borthwick, Mikayla S., Lau, Eric, Yates, Melinda S., Westin, Shannon N., Wani, Khalida, Tetzlaff, Michael T., Haydu, Lauren E., Mahendra, Mikhila, Ma, XiaoYan, Logothetis, Christopher, Kulstad, Zachary, Johnson, Sarah, Hudgens, Courtney W., Feng, Ningping, Federico, Lorenzo, Long, Georgina V., Futreal, P. Andrew, Arur, Swathi, Tawbi, Hussein A., Moran, Amy E., Wang, Linghua, Heffernan, Timothy P., Marszalek, Joseph R., and Wargo, Jennifer A.

Published
2022
Full Text
View/download PDF

6. Abstract A010: Mitochondrial depletion and metabolic reprogramming is a novel phenotype of Lynch syndrome-related endometrial carcinogenesis

Author

Bowen, Mikayla B., primary, Melendez, Brenda, additional, Zal, Anna, additional, Jeter, Collene, additional, Chan, Wai Kin, additional, Tan, Lin, additional, Lorenzi, Philip, additional, Moreno, Diana, additional, Peralta, Leah, additional, Zhang, Qian, additional, Gokul, Nisha, additional, Lu, Karen, additional, Kim, Hyun-Eui, additional, and Yates, Melinda S., additional

Published
2024
Full Text
View/download PDF

7. Abstract B024: Immune exhaustion and reversal of progestin-related immune modulation in adaptive resistance to levonorgestrel intrauterine device for treatment of atypical hyperplasia and early endometrial cancer

Author

Bowen, Mikayla B., primary, Melendez, Brenda, additional, Zhang, Qian, additional, Yang, Richard, additional, Fellman, Bryan, additional, Lawson, Barrett, additional, Adjei, Naomi, additional, Celestino, Joseph, additional, Nguyen, Tri, additional, Wani, Khalida, additional, Singh, Bhavana, additional, Straub, Christof, additional, Zhang, Liang, additional, Tan, Cheryl, additional, New, Felicia, additional, Urbauer, Diana, additional, Lazar, Alexander, additional, Lu, Karen, additional, Wargo, Jennifer, additional, Westin, Shannon N., additional, and Yates, Melinda S., additional

Published
2024
Full Text
View/download PDF

9. Molecular, Metabolic, and Subcellular Mapping of the Tumor Immune Microenvironment via 3D Targeted and Non-Targeted Multiplex Multi-Omics Analyses

Author

Ferri-Borgogno, Sammy, primary, Burks, Jared K., additional, Seeley, Erin H., additional, McKee, Trevor D., additional, Stolley, Danielle L., additional, Basi, Akshay V., additional, Gomez, Javier A., additional, Gamal, Basant T., additional, Ayyadhury, Shamini, additional, Lawson, Barrett C., additional, Yates, Melinda S., additional, Birrer, Michael J., additional, Lu, Karen H., additional, and Mok, Samuel C., additional

Published
2024
Full Text
View/download PDF

10. Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy

Author

Vellano, Christopher P., White, Michael G., Andrews, Miles C., Chelvanambi, Manoj, Witt, Russell G., Daniele, Joseph R., Titus, Mark, McQuade, Jennifer L., Conforti, Fabio, Burton, Elizabeth M., Lastrapes, Matthew J., Ologun, Gabriel, Cogdill, Alexandria P., Morad, Golnaz, Prieto, Peter, Lazar, Alexander J., Chu, Yanshuo, Han, Guangchun, Khan, M. A. Wadud, Helmink, Beth, Davies, Michael A., Amaria, Rodabe N., Kovacs, Jeffrey J., Woodman, Scott E., Patel, Sapna, Hwu, Patrick, Peoples, Michael, Lee, Jeffrey E., Cooper, Zachary A., Zhu, Haifeng, Gao, Guang, Banerjee, Hiya, Lau, Mike, Gershenwald, Jeffrey E., Lucci, Anthony, Keung, Emily Z., Ross, Merrick I., Pala, Laura, Pagan, Eleonora, Segura, Rossana Lazcano, Liu, Qian, Borthwick, Mikayla S., Lau, Eric, Yates, Melinda S., Westin, Shannon N., Wani, Khalida, Tetzlaff, Michael T., Haydu, Lauren E., Mahendra, Mikhila, Ma, XiaoYan, Logothetis, Christopher, Kulstad, Zachary, Johnson, Sarah, Hudgens, Courtney W., Feng, Ningping, Federico, Lorenzo, Long, Georgina V., Futreal, P. Andrew, Arur, Swathi, Tawbi, Hussein A., Moran, Amy E., Wang, Linghua, Heffernan, Timothy P., Marszalek, Joseph R., and Wargo, Jennifer A.

Published
2023
Full Text
View/download PDF

11. Salpingectomy as a Means to Reduce Ovarian Cancer Risk

Author

Daly, Mary B, Dresher, Charles W, Yates, Melinda S, Jeter, Joanne M, Karlan, Beth Y, Alberts, David S, and Lu, Karen H

Subjects
Prevention, Clinical Research, Estrogen, Cancer, Ovarian Cancer, Rare Diseases, Patient Safety, Aging, Genetics, Good Health and Well Being, Carcinoma, Ovarian Epithelial, Elective Surgical Procedures, Female, Humans, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Prophylactic Surgical Procedures, Risk Factors, Risk Reduction Behavior, Salpingectomy, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Bilateral salpingo-oophorectomy (BSO) has become the standard-of-care for risk reduction in women at hereditary risk of ovarian cancer. Although this procedure significantly decreases both the incidence of and mortality from ovarian cancer, it affects quality of life, and the premature cessation of ovarian function may have long-term health hazards. Recent advances in our understanding of the molecular pathways of ovarian cancer point to the fallopian tube epithelium as the origin of most high-grade serous cancers (HGSC). This evolving appreciation of the role of the fallopian tube in HGSC has led to the consideration of salpingectomy alone as an option for risk management, especially in premenopausal women. In addition, it is postulated that bilateral salpingectomy with ovarian retention (BSOR), may have a public health benefit for women undergoing benign gynecologic surgery. In this review, we provide the rationale for salpingectomy as an ovarian cancer risk reduction strategy.

Published
2015

14. Prospective Multicenter Randomized Intermediate Biomarker Study of Oral Contraceptive versus Depo-Provera for Prevention of Endometrial Cancer in Women with Lynch Syndrome

Author

Lu, Karen H, Loose, David S, Yates, Melinda S, Nogueras-Gonzalez, Graciela M, Munsell, Mark F, Chen, Lee-may, Lynch, Henry, Cornelison, Terri, Boyd-Rogers, Stephanie, Rubin, Mary, Daniels, Molly S, Conrad, Peggy, Milbourne, Andrea, Gershenson, David M, and Broaddus, Russell R

Subjects
Cancer, Rare Diseases, Uterine Cancer, Clinical Research, Contraception/Reproduction, Prevention, Adult, Antineoplastic Agents, Hormonal, Biomarkers, Tumor, Colorectal Neoplasms, Hereditary Nonpolyposis, Contraceptives, Oral, Endometrial Neoplasms, Female, Follow-Up Studies, Humans, Immunoenzyme Techniques, Medroxyprogesterone Acetate, Middle Aged, Mutation, Prognosis, Prospective Studies, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Women with Lynch syndrome have a 40% to 60% lifetime risk for developing endometrial cancer, a cancer associated with estrogen imbalance. The molecular basis for endometrial-specific tumorigenesis is unclear. Progestins inhibit estrogen-driven proliferation, and epidemiologic studies have shown that progestin-containing oral contraceptives (OCP) reduce the risk of endometrial cancer by 50% in women at general population risk. It is unknown whether they are effective in women with Lynch syndrome. Asymptomatic women ages 25 to 50 with Lynch syndrome were randomized to receive the progestin compounds Depo-Provera (depo-MPA) or OCP for three months. An endometrial biopsy and transvaginal ultrasound were conducted before and after treatment. Endometrial proliferation was evaluated as the primary endpoint. Histology and a panel of surrogate endpoint biomarkers were evaluated for each endometrial biopsy as secondary endpoints. A total of 51 women were enrolled, and 46 completed treatment. Two of the 51 women had complex hyperplasia with atypia at the baseline endometrial biopsy and were excluded from the study. Overall, both depo-MPA and OCP induced a dramatic decrease in endometrial epithelial proliferation and microscopic changes in the endometrium characteristic of progestin action. Transvaginal ultrasound measurement of endometrial stripe was not a useful measure of endometrial response or baseline hyperplasia. These results show that women with Lynch syndrome do show an endometrial response to short-term exogenous progestins, suggesting that OCP and depo-MPA may be reasonable chemopreventive agents in this high-risk patient population.

Published
2013

15. Supplementary Figure 1 from Another Surprise from Metformin: Novel Mechanism of Action via K-Ras Influences Endometrial Cancer Response to Therapy

Author

Iglesias, David A., primary, Yates, Melinda S., primary, van der Hoeven, Dharini, primary, Rodkey, Travis L., primary, Zhang, Qian, primary, Co, Ngai Na, primary, Burzawa, Jennifer, primary, Chigurupati, Sravanthi, primary, Celestino, Joseph, primary, Bowser, Jessica, primary, Broaddus, Russell, primary, Hancock, John F., primary, Schmandt, Rosemarie, primary, and Lu, Karen H., primary

Published
2023
Full Text
View/download PDF

16. Data from Prospective Multicenter Randomized Intermediate Biomarker Study of Oral Contraceptive versus Depo-Provera for Prevention of Endometrial Cancer in Women with Lynch Syndrome

Author

Lu, Karen H., primary, Loose, David S., primary, Yates, Melinda S., primary, Nogueras-Gonzalez, Graciela M., primary, Munsell, Mark F., primary, Chen, Lee-may, primary, Lynch, Henry, primary, Cornelison, Terri, primary, Boyd-Rogers, Stephanie, primary, Rubin, Mary, primary, Daniels, Molly S., primary, Conrad, Peggy, primary, Milbourne, Andrea, primary, Gershenson, David M., primary, and Broaddus, Russell R., primary

Published
2023
Full Text
View/download PDF

17. Commentary on This Article from Prospective Multicenter Randomized Intermediate Biomarker Study of Oral Contraceptive versus Depo-Provera for Prevention of Endometrial Cancer in Women with Lynch Syndrome

Author

Lu, Karen H., primary, Loose, David S., primary, Yates, Melinda S., primary, Nogueras-Gonzalez, Graciela M., primary, Munsell, Mark F., primary, Chen, Lee-may, primary, Lynch, Henry, primary, Cornelison, Terri, primary, Boyd-Rogers, Stephanie, primary, Rubin, Mary, primary, Daniels, Molly S., primary, Conrad, Peggy, primary, Milbourne, Andrea, primary, Gershenson, David M., primary, and Broaddus, Russell R., primary

Published
2023
Full Text
View/download PDF

19. Supplementary Table 1 from Prospective Multicenter Randomized Intermediate Biomarker Study of Oral Contraceptive versus Depo-Provera for Prevention of Endometrial Cancer in Women with Lynch Syndrome

Author

Lu, Karen H., primary, Loose, David S., primary, Yates, Melinda S., primary, Nogueras-Gonzalez, Graciela M., primary, Munsell, Mark F., primary, Chen, Lee-may, primary, Lynch, Henry, primary, Cornelison, Terri, primary, Boyd-Rogers, Stephanie, primary, Rubin, Mary, primary, Daniels, Molly S., primary, Conrad, Peggy, primary, Milbourne, Andrea, primary, Gershenson, David M., primary, and Broaddus, Russell R., primary

Published
2023
Full Text
View/download PDF

21. Supplementary Figure Legend from Prospective Multicenter Randomized Intermediate Biomarker Study of Oral Contraceptive versus Depo-Provera for Prevention of Endometrial Cancer in Women with Lynch Syndrome

Author

Lu, Karen H., primary, Loose, David S., primary, Yates, Melinda S., primary, Nogueras-Gonzalez, Graciela M., primary, Munsell, Mark F., primary, Chen, Lee-may, primary, Lynch, Henry, primary, Cornelison, Terri, primary, Boyd-Rogers, Stephanie, primary, Rubin, Mary, primary, Daniels, Molly S., primary, Conrad, Peggy, primary, Milbourne, Andrea, primary, Gershenson, David M., primary, and Broaddus, Russell R., primary

Published
2023
Full Text
View/download PDF

23. Supplementary Figure Legend from Another Surprise from Metformin: Novel Mechanism of Action via K-Ras Influences Endometrial Cancer Response to Therapy

Author

Iglesias, David A., primary, Yates, Melinda S., primary, van der Hoeven, Dharini, primary, Rodkey, Travis L., primary, Zhang, Qian, primary, Co, Ngai Na, primary, Burzawa, Jennifer, primary, Chigurupati, Sravanthi, primary, Celestino, Joseph, primary, Bowser, Jessica, primary, Broaddus, Russell, primary, Hancock, John F., primary, Schmandt, Rosemarie, primary, and Lu, Karen H., primary

Published
2023
Full Text
View/download PDF

25. Supplementary Figure 1 from Prospective Multicenter Randomized Intermediate Biomarker Study of Oral Contraceptive versus Depo-Provera for Prevention of Endometrial Cancer in Women with Lynch Syndrome

Author

Lu, Karen H., primary, Loose, David S., primary, Yates, Melinda S., primary, Nogueras-Gonzalez, Graciela M., primary, Munsell, Mark F., primary, Chen, Lee-may, primary, Lynch, Henry, primary, Cornelison, Terri, primary, Boyd-Rogers, Stephanie, primary, Rubin, Mary, primary, Daniels, Molly S., primary, Conrad, Peggy, primary, Milbourne, Andrea, primary, Gershenson, David M., primary, and Broaddus, Russell R., primary

Published
2023
Full Text
View/download PDF

26. Supplementary Figure 2 from Another Surprise from Metformin: Novel Mechanism of Action via K-Ras Influences Endometrial Cancer Response to Therapy

Author

Iglesias, David A., primary, Yates, Melinda S., primary, van der Hoeven, Dharini, primary, Rodkey, Travis L., primary, Zhang, Qian, primary, Co, Ngai Na, primary, Burzawa, Jennifer, primary, Chigurupati, Sravanthi, primary, Celestino, Joseph, primary, Bowser, Jessica, primary, Broaddus, Russell, primary, Hancock, John F., primary, Schmandt, Rosemarie, primary, and Lu, Karen H., primary

Published
2023
Full Text
View/download PDF

28. Supplementary Figure 2 from Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study

Author

Soliman, Pamela T., primary, Westin, Shannon N., primary, Iglesias, David A., primary, Fellman, Bryan M., primary, Yuan, Ying, primary, Zhang, Qian, primary, Yates, Melinda S., primary, Broaddus, Russell R., primary, Slomovitz, Brian M., primary, Lu, Karen H., primary, and Coleman, Robert L., primary

Published
2023
Full Text
View/download PDF

29. Supplementary Figure 1 from Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study

Author

Soliman, Pamela T., primary, Westin, Shannon N., primary, Iglesias, David A., primary, Fellman, Bryan M., primary, Yuan, Ying, primary, Zhang, Qian, primary, Yates, Melinda S., primary, Broaddus, Russell R., primary, Slomovitz, Brian M., primary, Lu, Karen H., primary, and Coleman, Robert L., primary

Published
2023
Full Text
View/download PDF

36. Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy

Author

Vellano, C, White, M, Andrews, M, Chelvanambi, M, Witt, R, Daniele, J, Titus, M, Mcquade, J, Conforti, F, Burton, E, Lastrapes, M, Ologun, G, Cogdill, A, Morad, G, Prieto, P, Lazar, A, Chu, Y, Han, G, Khan, M, Helmink, B, Davies, M, Amaria, R, Kovacs, J, Woodman, S, Patel, S, Hwu, P, Peoples, M, Lee, J, Cooper, Z, Zhu, H, Gao, G, Banerjee, H, Lau, M, Gershenwald, J, Lucci, A, Keung, E, Ross, M, Pala, L, Pagan, E, Segura, R, Liu, Q, Borthwick, M, Lau, E, Yates, M, Westin, S, Wani, K, Tetzlaff, M, Haydu, L, Mahendra, M, Ma, X, Logothetis, C, Kulstad, Z, Johnson, S, Hudgens, C, Feng, N, Federico, L, Long, G, Futreal, P, Arur, S, Tawbi, H, Moran, A, Wang, L, Heffernan, T, Marszalek, J, Wargo, J, Vellano, Christopher P., White, Michael G., Andrews, Miles C., Chelvanambi, Manoj, Witt, Russell G., Daniele, Joseph R., Titus, Mark, McQuade, Jennifer L., Conforti, Fabio, Burton, Elizabeth M., Lastrapes, Matthew J., Ologun, Gabriel, Cogdill, Alexandria P., Morad, Golnaz, Prieto, Peter, Lazar, Alexander J., Chu, Yanshuo, Han, Guangchun, Khan, M. A. Wadud, Helmink, Beth, Davies, Michael A., Amaria, Rodabe N., Kovacs, Jeffrey J., Woodman, Scott E., Patel, Sapna, Hwu, Patrick, Peoples, Michael, Lee, Jeffrey E., Cooper, Zachary A., Zhu, Haifeng, Gao, Guang, Banerjee, Hiya, Lau, Mike, Gershenwald, Jeffrey E., Lucci, Anthony, Keung, Emily Z., Ross, Merrick I., Pala, Laura, Pagan, Eleonora, Segura, Rossana Lazcano, Liu, Qian, Borthwick, Mikayla S., Lau, Eric, Yates, Melinda S., Westin, Shannon N., Wani, Khalida, Tetzlaff, Michael T., Haydu, Lauren E., Mahendra, Mikhila, Ma, XiaoYan, Logothetis, Christopher, Kulstad, Zachary, Johnson, Sarah, Hudgens, Courtney W., Feng, Ningping, Federico, Lorenzo, Long, Georgina V., Futreal, P. Andrew, Arur, Swathi, Tawbi, Hussein A., Moran, Amy E., Wang, Linghua, Heffernan, Timothy P., Marszalek, Joseph R., Wargo, Jennifer A., Vellano, C, White, M, Andrews, M, Chelvanambi, M, Witt, R, Daniele, J, Titus, M, Mcquade, J, Conforti, F, Burton, E, Lastrapes, M, Ologun, G, Cogdill, A, Morad, G, Prieto, P, Lazar, A, Chu, Y, Han, G, Khan, M, Helmink, B, Davies, M, Amaria, R, Kovacs, J, Woodman, S, Patel, S, Hwu, P, Peoples, M, Lee, J, Cooper, Z, Zhu, H, Gao, G, Banerjee, H, Lau, M, Gershenwald, J, Lucci, A, Keung, E, Ross, M, Pala, L, Pagan, E, Segura, R, Liu, Q, Borthwick, M, Lau, E, Yates, M, Westin, S, Wani, K, Tetzlaff, M, Haydu, L, Mahendra, M, Ma, X, Logothetis, C, Kulstad, Z, Johnson, S, Hudgens, C, Feng, N, Federico, L, Long, G, Futreal, P, Arur, S, Tawbi, H, Moran, A, Wang, L, Heffernan, T, Marszalek, J, Wargo, J, Vellano, Christopher P., White, Michael G., Andrews, Miles C., Chelvanambi, Manoj, Witt, Russell G., Daniele, Joseph R., Titus, Mark, McQuade, Jennifer L., Conforti, Fabio, Burton, Elizabeth M., Lastrapes, Matthew J., Ologun, Gabriel, Cogdill, Alexandria P., Morad, Golnaz, Prieto, Peter, Lazar, Alexander J., Chu, Yanshuo, Han, Guangchun, Khan, M. A. Wadud, Helmink, Beth, Davies, Michael A., Amaria, Rodabe N., Kovacs, Jeffrey J., Woodman, Scott E., Patel, Sapna, Hwu, Patrick, Peoples, Michael, Lee, Jeffrey E., Cooper, Zachary A., Zhu, Haifeng, Gao, Guang, Banerjee, Hiya, Lau, Mike, Gershenwald, Jeffrey E., Lucci, Anthony, Keung, Emily Z., Ross, Merrick I., Pala, Laura, Pagan, Eleonora, Segura, Rossana Lazcano, Liu, Qian, Borthwick, Mikayla S., Lau, Eric, Yates, Melinda S., Westin, Shannon N., Wani, Khalida, Tetzlaff, Michael T., Haydu, Lauren E., Mahendra, Mikhila, Ma, XiaoYan, Logothetis, Christopher, Kulstad, Zachary, Johnson, Sarah, Hudgens, Courtney W., Feng, Ningping, Federico, Lorenzo, Long, Georgina V., Futreal, P. Andrew, Arur, Swathi, Tawbi, Hussein A., Moran, Amy E., Wang, Linghua, Heffernan, Timothy P., Marszalek, Joseph R., and Wargo, Jennifer A.

Abstract

Treatment with therapy targeting BRAF and MEK (BRAF/MEK) has revolutionized care in melanoma and other cancers; however, therapeutic resistance is common and innovative treatment strategies are needed1,2. Here we studied a group of patients with melanoma who were treated with neoadjuvant BRAF/MEK-targeted therapy (NCT02231775, n = 51) and observed significantly higher rates of major pathological response (MPR; ≤10% viable tumour at resection) and improved recurrence-free survival (RFS) in female versus male patients (MPR, 66% versus 14%, P = 0.001; RFS, 64% versus 32% at 2 years, P = 0.021). The findings were validated in several additional cohorts2–4 of patients with unresectable metastatic melanoma who were treated with BRAF- and/or MEK-targeted therapy (n = 664 patients in total), demonstrating improved progression-free survival and overall survival in female versus male patients in several of these studies. Studies in preclinical models demonstrated significantly impaired anti-tumour activity in male versus female mice after BRAF/MEK-targeted therapy (P = 0.006), with significantly higher expression of the androgen receptor in tumours of male and female BRAF/MEK-treated mice versus the control (P = 0.0006 and P = 0.0025). Pharmacological inhibition of androgen receptor signalling improved responses to BRAF/MEK-targeted therapy in male and female mice (P = 0.018 and P = 0.003), whereas induction of androgen receptor signalling (through testosterone administration) was associated with a significantly impaired response to BRAF/MEK-targeted therapy in male and female patients (P = 0.021 and P < 0.0001). Together, these results have important implications for therapy.

Published
2022

37. Abstract 1248: Predictors of innate resistance to pembrolizumab in patients with microsatellite instability-high endometrial cancer

Author

How, Jeffrey A., primary, Dang, Minghao, additional, Ferri-Borgogno, Sammy, additional, Euscher, Elizabeth, additional, Yates, Melinda S., additional, Peng, Weiyi, additional, Patel, Shrina D., additional, Burks, Jared J., additional, Vletic, Ivo, additional, Gomez, Javier, additional, Lu, Karen, additional, Mok, Samuel C., additional, Wang, Linghua, additional, and Jazaeri, Amir A., additional

Published
2022
Full Text
View/download PDF

38. Targeting Nrf2 with the Triterpenoid CDDO-Imidazolide Attenuates Cigarette Smoke-Induced Emphysema and Cardiac Dysfunction in Mice

Author

Sussan, Thomas E., Rangasamy, Tirumalai, Blake, David J., Malhotra, Deepti, El-Haddad, Hazim, Bedja, Djahida, Yates, Melinda S., Kombairaju, Ponvijay, Yamamoto, Masayuki, Liby, Karen T., Sporn, Michael B., Gabrielson, Kathleen L., Champion, Hunter C., Tuder, Rubin M., Kensler, Thomas W., Biswal, Shyam, and Wogan, Gerald N.

Published
2009
Full Text
View/download PDF

42. Endometrial biomarkers in premenopausal women with obesity: an at-risk cohort

Author

Dottino, Joseph A., primary, Zhang, Qian, additional, Loose, David S., additional, Fellman, Bryan, additional, Melendez, Brenda D., additional, Borthwick, Mikayla S., additional, McKenzie, Laurie J., additional, Yuan, Ying, additional, Yang, Richard K., additional, Broaddus, Russell R., additional, Lu, Karen H., additional, Soliman, Pamela T., additional, and Yates, Melinda S., additional

Published
2021
Full Text
View/download PDF

43. Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer

Author

How, Jeffrey A., primary, Jazaeri, Amir A., additional, Fellman, Bryan, additional, Daniels, Molly S., additional, Penn, Suzanna, additional, Solimeno, Cara, additional, Yuan, Ying, additional, Schmeler, Kathleen, additional, Lanchbury, Jerry S., additional, Timms, Kirsten, additional, Lu, Karen H., additional, and Yates, Melinda S., additional

Published
2021
Full Text
View/download PDF

45. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer

Author

Westin, Shannon N., primary, Fellman, Bryan, additional, Sun, Charlotte C., additional, Broaddus, Russell R., additional, Woodall, Misty L., additional, Pal, Navdeep, additional, Urbauer, Diana L., additional, Ramondetta, Lois M., additional, Schmeler, Kathleen M., additional, Soliman, Pamela T., additional, Fleming, Nicole D., additional, Burzawa, Jennifer K., additional, Nick, Alpa M., additional, Milbourne, Andrea M., additional, Yuan, Ying, additional, Lu, Karen H., additional, Bodurka, Diane C., additional, Coleman, Robert L., additional, and Yates, Melinda S., additional

Published
2021
Full Text
View/download PDF

49. Abstract NG14: Proteome instability is an immunogenic therapeutic vulnerability in mismatch repair deficient cancer

Author

Sahni, Nidhi, primary, McGrail, Daniel J., additional, Garnett, Jeannine, additional, Yin, Jun, additional, Dai, Hui, additional, Shih, David J. H., additional, Peng, Guang, additional, Menter, David, additional, Yates, Melinda S., additional, Kopetz, Scott, additional, Lu, Karen, additional, Broaddus, Russell, additional, Mills, Gordon B., additional, and Lin, Shiaw Y., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results